We demonstrated that PKCδ inhibits the activation of the NF-κB signal pathway by binding and phosphorylating A20, which in turn reduces the expression of IL-33 and alleviates IPF, suggesting that PKCδ is a potential drug target for treating IPF. This evidence concerns the gene IL33 and idiopathic pulmonary fibrosis.